Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluate the Efficacy of Xuebijing Injection in Acute Exacerbations of COPD
NCT02937974Phase 4Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Oct 2016
- Primary completion
- Dec 2018
- Modality
- PE (Plant Extract)
- Countries
- 1
01
Overview
Phase 4, randomised trial in chronic obstructive pulmonary disease (COPD) comparing Xuebijing with Placebo (2 arms). Primary endpoint: Invasive mechanical ventilation rate at 28 days. Status: unknown.
02
Drugs
xuebijing
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02937974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02937974.